非典型溶血性尿毒症综合征患者接受依库珠单抗治疗时首剂脑膜炎球菌疫苗接种失败
该研究评估了非典型溶血性尿毒症综合征(aHUS)患者在开始依库珠单抗治疗前接种四价脑膜炎球菌疫苗(MenACWY)的免疫应答。25例患者中仅5例(20%)产生完全免疫应答,7例(28%)对任何血清群均无应答。再接种后17例中9例不完全应答者产生保护性抗体,但总体应答不充分,提示抗生素预防至关重要。
要点
- aHUS患者首剂MenACWY疫苗接种后仅20%产生完全免疫应答。
- 28%患者对所有测试血清群均无免疫应答。
- 再接种可改善部分患者应答,但仍不完全,需考虑抗生素预防。
核心结论
- aHUS患者首剂四价脑膜炎球菌疫苗接种免疫原性不足,再接种应答有希望但不完全,建立抗生素预防似乎至关重要。
研究设计与样本
- 研究纳入25例aHUS患者,在依库珠单抗治疗开始前接种一剂MenACWY结合疫苗,使用兔补体检测针对血清群A、C、W、Y的杀菌滴度。
主要发现
- 25例患者中5例(20%)对脑膜炎球菌疫苗产生完全免疫应答。
- 7例(28%)对任何测试血清群均无免疫应答。
- 再接种后杀菌滴度数据 available 于17例患者,其中9例首剂后不完全应答者在再接种后对所有血清群均显示保护性抗体滴度。
- 再接种时与首次接种时相比,超过50%的患者肾功能改善,且免疫抑制治疗仅用于肾移植后再接种的患者。
临床怎么用
- 对于接受依库珠单抗治疗的aHUS患者,即使接种疫苗,仍应考虑抗生素预防以降低脑膜炎球菌感染风险。
- 再接种可能改善部分患者的免疫应答,但需评估个体应答情况。
局限性
- 再接种后杀菌滴度数据仅 available 于17例患者,样本量有限。
- 未报告长期临床结局与感染事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The C5 complement inhibitor eculizumab is a first-line treatment in atypical haemolytic uraemic syndrome (aHUS). Therapy with eculizumab is associated with a highly increased risk for meningococcal infection. Therefore, vaccination is highly recommended before beginning treatment. Efficacy of quadrivalent meningococcal vaccines (MenACWY) in patients treated with the C5 complement inhibitor eculizumab in aHUS has not yet been determined. METHODS: Patients with aHUS received one dose of a MenACWY conjugate vaccine before eculizumab treatment commenced. Bactericidal titres against meningococcal serogroups A, C, W and Y were determined using baby rabbit complement in 25 patients. RESULTS: Full immune response to meningococcal vaccination was detected in five patients (20%), while seven patients (28%) showed no immune response in any of the tested serogroups. The remaining 13 patients showed incomplete immune response with proof of protective antibody titres for one to three serogroups without perceptible preference for any serogroup. Bactericidal titres after re-vaccination were available for 17 patients. Nine patients with incomplete immune response after first vaccinations showed protective antibody titres for all serogroups after re-vaccination. Kidney function had improved in >50% of patients at the time of re-vaccination compared with the time of first vaccination and immunosuppressive therapy was only applied to re-vaccinated patients following kidney transplantation. CONCLUSIONS: Immunogenicity of first quadrivalent meninongococcal vaccination is insufficient in patients with aHUS. Booster response is promising, but incomplete. Therefore, establishing antibiotic prophylaxes seems pivotal.
引用
- Gäckler A, Kaulfuß M, Rohn H, et al. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol Dial Transplant. 2020. PMID: 29992261. doi:10.1093/ndt/gfy225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。